A Phase 3 interventional study of rivaroxaban and ASA and Low-molecular weight heparin in Hip Fracture Surgery, Cardiovascular Prevention and Venous Thromboembolism (VTE), sponsored by McMaster University. Not yet recruiting at 3 sites in 2 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2025-11-14.
Sponsored by McMaster University · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 46th largest by planned enrollment, is one of 5 that started in 2025, is one of 26 in phase 3, reaches primary completion later than 13 of the 17 other live ones, and was the 56th registered.
714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.
Browse Venous Thromboembolism studies →18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:
Military Hospital of Tunis · Sites in Tunisia
Ages 18–80
Wolfson Medical Center · Sites in Israel
Ages 18–50 · Women only
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Thomas Jefferson University · Sites in United States
Ages 18+ · Women only
Medical University of Gdansk · Sites in Poland
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 29 · Phase 4 12
First in 2004; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 272 across the 61 interventional studies. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 61 have an industry lead sponsor. The 10 most frequent:
McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.
14 studies in Venous Thromboembolism by McMaster University: 2 open now, 2 under way, 1 of them phase 3. Of 12 finished, 0 (0%) have results posted.
Among the 14 studies in Venous Thromboembolism by McMaster University, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 3, and was the 14th registered.
McMaster University’s Venous Thromboembolism studies by the year they started, since 1998.
8 of the studies testing rivaroxaban in Venous Thromboembolism that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05029063Phase 3Ottawa Hospital Research InstitutePrimary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters | 2026-12 |
| NCT07228663Phase 3McMaster UniversityHip Fracture Surgery Arterial and Venous Thrombotic Events Prevention | 2027-07-01 |
| NCT06580223Phase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | 2027-09-01 |
| NCT04874428Insel Gruppe AG, University Hospital BernDirect Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis | 2026-12 |
| NCT07907211Chen LijuanAspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma | 2026-12-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 61 studies testing rivaroxaban in Venous Thromboembolism, from their registry updates:
Among McMaster University’s 14 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rivaroxaban 2.5mg twice daily plus ASA 75-100mg daily for 90 days
Drug: rivaroxaban and ASA
Institution's standard of care for thromboprophylaxis with a low-dose anticoagulant for \~30 days (as per the standard of care). Regimens could include low-molecular-weight heparin, fondaparinux, or direct oral anticoagulant.
Drug: Low-molecular weight heparin · Drug: Fondaparinux · Drug: Direct Oral Anticoagulant (DOAC)
Drug pages: RivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
rivaroxaban 2.5 mg orally BID and ASA 75-100 mg OD for 90 days
Also known as: acetylsalicylic acid, Xarelto
Enoxaparin: 40 mg subcutaneously OD (or 30 mg subcutaneously BID); Dalteparin: 5000 IU subcutaneously OD (or alternative dosing based on institutional protocol); Tinzaparin: 4500 IU subcutaneous OD
Also known as: enoxaparin, dalteparin, tinzaparin
2.5 mg subcutaneously OD
Also known as: arixtra
Rivaroxaban 10 mg OD or apixaban 2.5 mg BID, started after surgery or after a period of LMWH.
Also known as: rivaroxaban, apixaban
Recruitment rate
Number of patients recruited per month per site
Time frame: Through study completion, an average of 1 year.
FUP completion
Proportion of patients with a complete follow up
Time frame: assessed at 30 and 90 days
Treatment adherence
Proportion of number of days on treatment
Time frame: 30 and 90 days for the intervention, pre-specified treatment duration as per standard of care for the control.
all-cause mortality, MI, non-hemorrhagic stroke, peripheral arterial thrombosis, and symptomatic objectively confirmted VTE
Composite. Also each individual component will be assessed.
Time frame: From randomization to 90 days post-randomization.
Cardiovascular mortality
Time frame: From randomization to 90 days post-randomization.
Major bleeding events
Major bleeding events as defined by the ISTH.
Time frame: From randomization to 90 days post-randomization.
Clinically relevant nonmajor bleeding
Time frame: From randomization to 90 days post-randomization.
Minor bleeding
Time frame: From randomization to 90 days post-randomization.
Bleeding independently associated with mortality after non-cardiac surgery (BIMS)
Bleeding leading to a postoperative haemoglobin \<70 g/L, transfusion of 1 unit of red blood cells, or bleeding that was judged to be the cause of death.
Time frame: From randomization to 90 days post-randomization.
Quality of life (EQ-5D-5L)
Measured with EQ-5D-5L
Time frame: 90 days
Hospitalizations
The length of stay and re-hospitalizations as measures of resource utilization.
Time frame: From randomization to 90-days post randomization.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Available to share upon reasonable request, but will likely not unblind before completing a full-scale trial.
Start is estimated for Dec 2025; primary completion for Jul 2027, 19 months later.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Aspirin